Skip to main content

Table 2 Change of clinical and laboratory characteristics before and after ALA treatment

From: α-Linolenic acid increases the G0/G1 switch gene 2 mRNA expression in peripheral blood mononuclear cells from obese patients: a pilot study

Parameters ALA (n = 14)   Control (n = 12)  
Baseline After 12 weeks p Baseline After 12 weeks p
Age (years) 48.6 ± 6.8    49.3 ± 4.8   
Body weight (kg) 93.6 ± 6.6 89.8 ± 5.8 0.116 95.3 ± 6.6 92.6 ± 6.7 0.335
BMI (kg/m2) 32.3 ± 1.2 31.0 ± 1.3 0.009* 32.7 ± 1.0 31.8 ± 0.8 0.018*
TC (mmol/L) 5.01 ± 0.48 4.79 ± 0.42 0.209 5.17 ± 0.45 5.01 ± 0.41 0.381
TG (mmol/L) 3.59 ± 0.65 1.73 ± 0.31 <0.0001* 3.73 ± 0.63 2.63 ± 0.54 0.048*
FFA (μmol/L) 655 ± 324 469 ± 29 <0.0001* 662 ± 28 501 ± 28 <0.0001*
Glycerol (μmol/L) 1505 ± 27 1028 ± 82 <0.0001* 1538 ± 83 1201 ± 94 <0.0001*
IL-6 (ng/L) 2.34 ± 0.14 1.53 ± 0.14 <0.0001* 2.37 ± 0.15 1.87 ± 0.12 <0.0001*
TNF-α (ng/L) 1.92 ± 0.14 1.28 ± 0.10 <0.0001* 1.92 ± 0.16 1.63 ± 0.15 <0.0001*
  1. Data are means ± SD
  2. Baseline vs After 12 weeks, two-sample t test, *p < 0.05